| | |
|---|---|
| **NCT ID** | NCT03084471 |
| **Title** | An Open-Label, Multi-Centre, Study to Assess the Safety of Fixed-Dose Durvalumab + Tremelimumab Combination Therapy or Durvalumab Monotherapy in Advanced Solid Malignancies. |
| **Phase** | Phase 3 |
| **Date Added** | 2017-03-21 |
| **Location** | California, United States<br>District of Columbia, United States<br>Illinois, United States<br>Nebraska, United States<br>New Jersey, United States<br>New York, United States<br>South Carolina, United States<br>Tennessee, United States<br>Virginia, United States<br>Washington, United States<br>Canada<br>France<br>Germany<br>Italy<br>Korea, Republic of<br>Netherlands<br>United Kingdom |
| **IO -centered** | No |
| **Prior IO Allowed** | No |
| **CRC-directed** | No |
| **Status** | Active, not recruiting |
| **Drugs** | MEDI4736 (Durvalumab), MEDI4736 (Durvalumab) + Tremelimumab |

---

| | |
|---|---|
| **NCT ID** | NCT05198934 |
| **Title** | Sotorasib and Panitumumab Versus Investigator's Choice for Participants With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation (CodeBreak 300) |
| **Phase** | Phase 3 |
| **Date Added** | 2022-01-20 |
| **Location** | Alabama, United States<br>California, United States<br>District of Columbia, United States<br>Florida, United States<br>Georgia, United States<br>Michigan, United States<br>New York, United States<br>North Carolina, United States<br>Ohio, United States<br>Pennsylvania, United States<br>Tennessee, United States<br>Texas, United States<br>Australia<br>France<br>Germany<br>Greece<br>Italy<br>Japan<br>Korea, Republic of<br>Mexico<br>Spain<br>Taiwan<br>United Kingdom |
| **IO -centered** | No |
| **Prior IO Allowed** | Yes |
| **CRC-directed** | Yes |
| **Status** | Recruiting |
| **Drugs** | |

---

| | |
|---|---|
| **NCT ID** | NCT05141721 |

| | |
|---|---|
| **Title** | A Study of a Personalized Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer |
| **Phase** | Phase 2, Phase 3 |
| **Date Added** | 2021-12-02 |
| **Location** | Arizona, United States<br>Arkansas, United States<br>California, United States<br>Colorado, United States<br>Connecticut, United States<br>Florida, United States<br>Illinois, United States<br>Indiana, United States<br>Kansas, United States<br>Kentucky, United States<br>Maryland, United States<br>Michigan, United States<br>Nevada, United States<br>New Jersey, United States<br>New York, United States<br>North Carolina, United States<br>Ohio, United States<br>Oregon, United States<br>Pennsylvania, United States<br>South Carolina, United States<br>Tennessee, United States<br>Texas, United States<br>Utah, United States<br>Virginia, United States<br>Washington, United States<br>Wisconsin, United States |
| **IO -centered** | No |
| **Prior IO Allowed** | No |
| **CRC-directed** | Yes |
| **Status** | Recruiting |
| **Drugs** | Atezolizumab, Bevacizumab, Fluoropyrimidine, GRT-C901, GRT-R902, Ipilimumab, oxaliplatin |

---

| | |
|---|---|
| **NCT ID** | NCT04607421 |
| **Title** | A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer (BREAKWATER) |
| **Phase** | Phase 3 |
| **Date Added** | 2020-10-29 |

| | |
|---|---|
| **Location** | Arizona, United States<br>California, United States<br>District of Columbia, United States<br>Florida, United States<br>Georgia, United States<br>Illinois, United States<br>Louisiana, United States<br>Michigan, United States<br>Minnesota, United States<br>Missouri, United States<br>Montana, United States<br>Nebraska, United States<br>New Jersey, United States<br>New York, United States<br>North Carolina, United States<br>Ohio, United States<br>Oklahoma, United States<br>Oregon, United States<br>Pennsylvania, United States<br>Tennessee, United States<br>Texas, United States<br>Virginia, United States<br>Washington, United States<br>Wisconsin, United States<br>Argentina<br>Australia<br>Belgium<br>Brazil<br>Bulgaria<br>Canada<br>China<br>Czechia<br>Denmark<br>Finland<br>Germany<br>India<br>Italy<br>Japan<br>Korea, Republic of<br>Mexico<br>Netherlands<br>New Zealand<br>Norway<br>Poland<br>Russian Federation<br>Slovakia<br>South Africa<br>Spain<br>Sweden<br>Taiwan<br>Ukraine<br>United Kingdom |
| **IO -centered** | No |
| **Prior IO Allowed** | No |
| **CRC-directed** | Yes |
| **Status** | Recruiting |
| **Drugs** | 5-FU, Bevacizumab, capecitabine, cetuximab, encorafenib, Irinotecan, Leucovorin, oxaliplatin |

---

| | |
|---|---|
| **NCT ID** | NCT05328908 |
| **Title** | A Study of Nivolumab-relatlimab Fixed-dose Combination Versus Regorafenib or TAS-102 in Participants With Later-lines of Metastatic Colorectal Cancer |
| **Phase** | Phase 3 |
| **Date Added** | 2022-04-14 |

| | |
|---|---|
| **Location** | Arkansas, United States<br>California, United States<br>Connecticut, United States<br>Florida, United States<br>Georgia, United States<br>Idaho, United States<br>Illinois, United States<br>Indiana, United States<br>Massachusetts, United States<br>Michigan, United States<br>Minnesota, United States<br>New Jersey, United States<br>North Carolina, United States<br>Ohio, United States<br>Pennsylvania, United States<br>South Carolina, United States<br>South Dakota, United States<br>Tennessee, United States<br>Texas, United States<br>Virginia, United States<br>Wisconsin, United States<br>Argentina<br>Australia<br>Austria<br>Belgium<br>Canada<br>Chile<br>China<br>Czechia<br>France<br>Germany<br>Italy<br>Japan<br>Korea, Republic of<br>Netherlands<br>Poland<br>Puerto Rico<br>Singapore<br>Spain<br>Sweden<br>Switzerland<br>Taiwan |
| **IO -centered** | No |
| **Prior IO Allowed** | No |
| **CRC-directed** | Yes |
| **Status** | Recruiting |
| **Drugs** | Nivolumab-relatlimab FDC, Regorafenib, TAS-102, Lonsurf, Opdivo, Stivarga |

---

| | |
|---|---|
| **NCT ID** | NCT05223673 |
| **Title** | Phase 3 Study of Futuximab/Modotuximab in Combination With Trifluridine/Tipiracil Versus Trifluridine/Tipiracil Single Agent in Participants With Previously Treated Metastatic Colorectal Cancer |
| **Phase** | Phase 3 |
| **Date Added** | 2022-02-04 |
| **Location** | Michigan, United States<br>Ohio, United States<br>Belgium<br>Denmark<br>Finland<br>Japan |
| **IO -centered** | No |
| **Prior IO Allowed** | No |
| **CRC-directed** | Yes |
| **Status** | Recruiting |
| **Drugs** | Futuximab/modotuximab, Trifluridine/Tipiracil |

---

| | |
|---|---|
| **NCT ID** | NCT02928224 |
| **Title** | Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer |
| **Phase** | Phase 3 |
| **Date Added** | 2016-10-10 |
| **Location** | Arizona, United States<br>California, United States<br>Colorado, United States<br>Connecticut, United States<br>Florida, United States<br>Illinois, United States<br>Indiana, United States<br>Iowa, United States<br>Kansas, United States<br>Louisiana, United States<br>Maryland, United States<br>Massachusetts, United States<br>Minnesota, United States<br>Missouri, United States<br>New Jersey, United States<br>New York, United States<br>Ohio, United States<br>Oregon, United States<br>Tennessee, United States<br>Texas, United States<br>Washington, United States<br>Wisconsin, United States<br>Argentina<br>Australia<br>Austria<br>Belgium<br>Brazil<br>Canada<br>Chile<br>Czechia<br>Denmark<br>France<br>Germany<br>Hungary<br>Israel<br>Italy<br>Japan<br>Korea, Republic of<br>Mexico<br>Netherlands<br>Norway<br>Poland<br>Russian Federation<br>Spain<br>Taiwan<br>Turkey<br>Ukraine<br>United Kingdom |
| **IO -centered** | No |
| **Prior IO Allowed** | Yes |
| **CRC-directed** | Yes |
| **Status** | Active, not recruiting |
| **Drugs** | 5-Fluorouracil, Binimetinib, cetuximab, encorafenib, Folinic acid, Irinotecan |

---

| | |
|---|---|
| **NCT ID** | NCT04607668 |
| **Title** | Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer (mCRC): |
| **Phase** | Phase 3 |
| **Date Added** | 2020-10-29 |

| | |
|---|---|
| **Location** | Arizona, United States<br>California, United States<br>District of Columbia, United States<br>Florida, United States<br>Georgia, United States<br>Illinois, United States<br>Massachusetts, United States<br>Minnesota, United States<br>Nevada, United States<br>Oklahoma, United States<br>Oregon, United States<br>Pennsylvania, United States<br>Tennessee, United States<br>Texas, United States<br>Virginia, United States<br>China<br>Hungary<br>Italy<br>Poland<br>Spain<br>Ukraine<br>United Kingdom |
| **IO -centered** | No |
| **Prior IO Allowed** | No |
| **CRC-directed** | Yes |
| **Status** | Active, not recruiting |
| **Drugs** | Placebo, Trilaciclib |

---

| | |
|---|---|
| **NCT ID** | NCT04793958 |
| **Title** | Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10) |
| **Phase** | Phase 3 |
| **Date Added** | 2021-03-11 |

| | |
|---|---|
| **Location** | Alabama, United States<br>Arizona, United States<br>Arkansas, United States<br>California, United States<br>Colorado, United States<br>Connecticut, United States<br>Florida, United States<br>Georgia, United States<br>Illinois, United States<br>Iowa, United States<br>Louisiana, United States<br>Maryland, United States<br>Massachusetts, United States<br>Michigan, United States<br>Minnesota, United States<br>Missouri, United States<br>Nebraska, United States<br>Nevada, United States<br>New Jersey, United States<br>New York, United States<br>North Carolina, United States<br>Ohio, United States<br>Oklahoma, United States<br>South Carolina, United States<br>Tennessee, United States<br>Texas, United States<br>Utah, United States<br>Virginia, United States<br>Washington, United States<br>West Virginia, United States<br>Wisconsin, United States<br>Argentina<br>Australia<br>Austria<br>Belgium<br>Brazil<br>Canada<br>China<br>Colombia<br>Czechia<br>Denmark<br>Finland<br>France<br>Germany<br>Greece<br>Hong Kong<br>Ireland<br>Italy<br>Korea, Republic of<br>Malaysia<br>Mexico<br>Netherlands<br>Poland<br>Portugal<br>Puerto Rico<br>Singapore<br>Spain<br>Taiwan<br>Thailand<br>United Kingdom |
| **IO -centered** | No |
| **Prior IO Allowed** | Yes |
| **CRC-directed** | Yes |
| **Status** | Recruiting |
| **Drugs** | cetuximab, FOLFIRI Regimen, mFOLFOX6 Regimen, MRTX849 |

---

| | |
|---|---|
| **NCT ID** | NCT04776148 |
| **Title** | Study of Lenvatinib (MK-7902/E7080) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care in Participants With Metastatic Colorectal Cancer (MK-7902-017/E7080-G000-325/LEAP-017) |

| | |
|---|---|
| **Phase** | Phase 3 |
| **Date Added** | 2021-03-01 |
| **Location** | California, United States<br>Georgia, United States<br>Illinois, United States<br>Maryland, United States<br>Michigan, United States<br>Montana, United States<br>Oregon, United States<br>Pennsylvania, United States<br>Virginia, United States<br>Washington, United States<br>Argentina<br>Australia<br>Canada<br>China<br>Denmark<br>Germany<br>Israel<br>Japan<br>Korea, Republic of<br>Russian Federation<br>Spain<br>Taiwan<br>Turkey<br>United Kingdom |
| **IO -centered** | No |
| **Prior IO Allowed** | No |
| **CRC-directed** | Yes |
| **Status** | Active, not recruiting |
| **Drugs** | Lenvatinib, Pembrolizumab, Regorafenib, TAS-102 (trifluridine and tipiracil) |